AHA: Amarin's Vascepa halts progression of arterial plaque in key study

One year after a cardiovascular outcomes study for Amarin's Vascepa took the American Heart Association Scientific Sessions by storm, the fish-oil pill is back—and on the verge of something big.

WIth an FDA decision to expand Vascepa's label to include CV risk reduction looming, a new imaging study now shows Vascepa could have an effect on stopping the progression of plaque in the arteries. Those results, which help explain Vascepa's mechanism of action, could give physicians even more reason to prescribe the drug if it nabs its expanded label.